Disclosure of trading in own shares

Paris (France), 14 May 2009 – Ipsen (Euronext: IPN) declares below the transactions made on its own shares for the period from 6 May 2009 until 13 May 2009.

Ipsen S.A.
a French company with a registered share capital of 84 059 683 €
Registered office: 65, quai Georges Gorse – 92100 Boulogne Billancourt (France)
Registered at the Nanterre Commercial and Companies Registry under number 419 838 529
RCS Nanterre

<table>
<thead>
<tr>
<th>Date</th>
<th>Type</th>
<th>Shares</th>
<th>Weighted Average Price (€)</th>
<th>Amount (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/05/2009</td>
<td>Purchase</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>07/05/2009</td>
<td>Purchase</td>
<td>13,591</td>
<td>31.032</td>
<td>421,750</td>
</tr>
<tr>
<td>08/05/2009</td>
<td>Purchase</td>
<td>15,000</td>
<td>30.661</td>
<td>459,915</td>
</tr>
<tr>
<td>11/05/2009</td>
<td>Purchase</td>
<td>30,000</td>
<td>30.626</td>
<td>918,793</td>
</tr>
<tr>
<td>12/05/2009</td>
<td>Purchase</td>
<td>30,000</td>
<td>31.199</td>
<td>935,970</td>
</tr>
<tr>
<td>13/05/2009</td>
<td>Purchase</td>
<td>30,000</td>
<td>31.781</td>
<td>953,430</td>
</tr>
<tr>
<td>Total</td>
<td>Purchase</td>
<td>118,591</td>
<td>31.114</td>
<td>3,689,858</td>
</tr>
</tbody>
</table>

About Ipsen
Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neurology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about €183 million, close to 19% of consolidated sales, which amounted to €971 million while total revenues exceeded €1 billion. Ipsen’s shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen’s shares are eligible to the “Service de Règlement Différé” (“SRD”) and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.Ipsen.com.

For further information
Didier Véron
Director, Public Affairs and Corporate Communications
Tél.: +33 (0)1 58 33 51 16 / Fax: +33 (0)1 58 33 50 58
e-mail: didier.veron@ipsen.com

David Schilansky
Investor Relations and Financial Officer
Tél.: +33 (0)1 58 33 51 30
Fax: +33 (0)1 58 33 50 63
e-mail : david.schilansky@ipsen.com

Pierre Kemula
Investor Relations Manager
Tél.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
e-mail : pierre.kemula@ipsen.com